Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience

Vybion Signs Agreement in Principle to Sell Line of Recombinant Proteins to Meridian Bioscience

ITHACA, N.Y. -- Vybion, Inc., an Ithaca-based biotechnology company, today announced that it has executed a letter of intent to sell its recombinant protein business to Meridian Bioscience, Inc. (NASDAQ: VIVO). The planned transaction, which both Vybion and Meridian expect will be completed within the next 60 days, calls for Vybion to receive both cash and future royalties based on sales of the applicable products, the amounts of which were not disclosed. Completion of the transaction is subject to execution of a definitive purchase agreement, satisfactory due diligence, and other customary conditions.

Dr. Lee Henderson, founder and CEO of Vybion, explained "This is an excellent opportunity for both companies. For Vybion it means that we can focus and internally fund proprietary activities, namely moving CoMab, our monoclonal antibody preclinical drug for Cocaine abuse, forward and commercialize our ProCode Platform technology.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.